Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of tiopronin in preparing medicament for treating liver function damage induced by cerebral ischemia, diabetes and obesity

A technology of tiopronin and cerebral ischemia, applied in the field of application of tiopronin in the preparation of drugs for the treatment of liver function damage secondary to cerebral ischemia, diabetes, and obesity, can solve the lack of mechanism-specific treatment Measures and other issues

Inactive Publication Date: 2009-01-28
WUHAN UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] For the cases of liver injury secondary to cerebral ischemia, obesity and diabetes, general non-specific hepatoprotective drugs are often used clinically, and there is a lack of specific treatment measures targeting the mechanism

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of tiopronin in preparing medicament for treating liver function damage induced by cerebral ischemia, diabetes and obesity
  • Use of tiopronin in preparing medicament for treating liver function damage induced by cerebral ischemia, diabetes and obesity
  • Use of tiopronin in preparing medicament for treating liver function damage induced by cerebral ischemia, diabetes and obesity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Embodiment 1: the pharmaceutical composition of the present invention consists of 100 grams of tiopronin, 30 grams of carboxymethylcellulose, 20 grams of sucrose, 50 grams of medicinal starch (or select other pharmaceutically acceptable carriers and / or excipients such as Maltose, etc.), made into 1000 capsules. The preparation method is as follows: the mixture of tiopronin and pharmaceutically acceptable carriers and / or excipients is placed in the feed pot of a centrifugal coating granulator to form granules, and then filled with enteric-coated capsules, each capsule containing tiopronin 100mg.

Embodiment 2

[0024] Embodiment 2: The pharmaceutical composition of the present invention consists of 100 grams of tiopronin, plus 50 grams of maltose, or select other pharmaceutically acceptable carriers and / or excipients such as sucrose, fructose, etc., add water for injection to 1000ml, and pack into 1000 made. The preparation method is as follows: dissolve 100 grams of tiopronin and 50 grams of maltose in 1 liter of water for injection, fully stir and dissolve, add 0.01 to 0.1% activated carbon for injection to absorb pyrogens, filter to remove activated carbon, and positive pressure microporous filtration to sterilize , subpackaged, each containing 100mg tiopronin.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to tiopronin or medical new use of the sodium salt thereof, in particular to the application of the tiopronin or the sodium salt thereof in the preparation of medicine for treating liver functional damage caused by cerebral ischemia, diabetes and obesity. The tiopronin has the function of specifically inhibiting liver cytochrome P450 2E1 (CYP2E1), there protecting the liver function from being damaged caused by cerebral ischemia, diabetes and obesity, so as to be a new clinical use having direction. The new use further expands the medical value of the tiopronin, which is taken as an inhibitor of liver CYP2E1 for protecting the function of liver, thus having important medical value, social and economic benefits.

Description

1. Technical field [0001] The invention relates to the use of tiopronin as a cytochrome P450 2E1 (CYP2E1) inhibitor in the preparation of medicines for treating liver function damage secondary to cerebral ischemia, obesity and diabetes. 2. Background technology [0002] Tiopronin (English name Tiopronin, chemical name: mercaptopropionylglycine), its molecular formula: C 5 h 9 NO 3 SH, molecular weight: 163.2, structural formula as follows: [0003] [0004] The liver is the main organ for the transformation and metabolism of various substances in the body. It expresses a variety of enzyme systems involved in the metabolism of substances, the most important of which is cytochrome P450 (CYPs for short). CYPs is a superfamily enzyme system with multiple subtypes, which metabolizes a variety of endogenous substances (substances synthesized by the body's own metabolism) and exogenous substances (including drugs, environmental toxicants, etc.), and is mainly expressed in the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/195A61P9/10A61P3/10A61P3/06A61P1/16
Inventor 彭仁琇乐江
Owner WUHAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products